



I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 5th day of May, 2003.

By

*Kristina L. Konstas*  
(Signature of person mailing)  
Kristina L. Konstas

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Mark A. Sanner, et al.

APPLICATION NO.: 09/919,630

FILING DATE: July 31, 2001

TITLE: IMIDAZOLE DERIVATIVES

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA. 2313-1450

Examiner: Rebecca L. Anderson

Group Art Unit: 1626  
MAY 09 2003

TECH CENTER 1800/2900

Sir:

INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicants herein make available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the following references cited by the applicants, copies of which are enclosed. References EP 0898963, EP 0933365, U.S. 5,760,246, EP 0573271, WO 00/49037, WO 00/21550, WO 99/65897, and EP 1106180, below, were cited in the International Search Report (IRS) issued in connection with a Patent Cooperation Treaty International Application corresponding to the subject application. A copy of said ISR is also enclosed.

Please charge the fee of \$180.00 required under 37 C.F.R. 1.17 (p) for filing this Information Disclosure Statement to Deposit Account No. 16-1445. No other fee is believed necessary for filing this Information Disclosure Statement. However, if any other fee is required for this submission such fee may also be charged to Deposit Account No. 16-1445.

1. United States Patent 5,760,246, June 2, 1998, Biller, et al.;
2. United States Patent 5,777,195, July 7, 1998, Fienberg, et al.;
3. United States Patent 6,013,621, January 11, 2000, Nishi, et al.;
4. EP 0 933 365, August 4, 1999, Eli Lilly and Company;
5. EP 0 898 963, March 3, 1999, Eli Lilly and Company;
6. EP 0 573 271, December 8, 1993, Eli Lilly and Company;

7. EP 1 106 180, June 13, 2001, Centre National De La Recherche Scientifique (CNRS);
8. WO 00/21550, April 20, 2000, President and Fellows of Harvard College;
9. WO 99/65897, December 23, 1999, Chiron Corporation;
10. WO 00/49037, August 24, 2000, Eli Lilly and Company;
11. Bibb, James A., et al., Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons, Nature, Vol. 402, Dec. 9, (1999);
12. Selic, Lovro and Stanovnik, Branko, Transformation of Methyl 2-(2,2-Disubstituted-ethenyl)amino-3-dimethylaminopropenoates. The Synthesis of Methyl 1-Heteroaryl-1H-imidazole-4-carboxylates, J. Heterocyclic Chemistry, vol. 35, p. 1527 (1998); and
13. Nunami, Ken-ichi, et al., A Novel Synthesis of Methyl 1,5-Disubstituted Imidazole-4-carboxylates Using 3-Bromo-2-isocyanoacrylates, J. Org. Chem, vol 59, 7635-7642 (1994).

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a).


It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445.

A prompt and favorable response is earnestly solicited.

Date: May 5, 2003

Respectfully submitted,



Kristina L. Konstas  
Attorney for Applicant(s)  
Reg. No. 37,864

Pfizer Inc  
Patent Department, 5th Floor  
150 East 42nd Street  
New York, NY 10017-5755  
(212)733 -6380